synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-11. Numbers and descriptions here follow the published literature rather than marketing material.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
marked insulin resistance (diabetes mellitus, metabolic syndrome) androgen excess (acromegaly, Cushing's disease, polycystic ovary syndrome) Addison's disease and hypothyroidism rare syndromes including Alström syndrome, Prader–Willi syndrome, Donohue syndrome, pinealoma, lipoatrophic diabetes, pituitary basophilism, pineal hyperplasia, ovarian hyperthecosis, stromal luteoma and ovarian dermoid cysts This form usually has a gradual onset and often occurs in people who are also obese.
Estradiol is known to correlate with aggression in male mice. Moreover, the conversion of testosterone to estradiol regulates male aggression in sparrows during breeding season. Rats who were given anabolic steroids that increase testosterone were also more physically aggressive to provocation as a result of "threat sensitivity". The relationship between testosterone and aggression may also function indirectly, as it has been proposed that testosterone does not amplify tendencies towards aggression, but rather amplifies whatever tendencies will allow an individual to maintain social status when challenged. In most animals, aggression is the means of maintaining social status. However, humans have multiple ways of obtaining status. This diversity could explain why some studies find a link between testosterone and pro-social behavior, if pro-social behavior is rewarded with social status. Thus the link between testosterone and aggression and violence is due to these being rewarded with social status. The relationship may also be one of a "permissive effect" whereby testosterone does elevate aggression levels, but only in the sense of allowing average aggression levels to be maintained; chemically or physically castrating the individual will reduce aggression levels (though not eliminate them) but the individual only needs a small-level of pre-castration testosterone to have aggression levels to return to normal, which they will remain at even if additional testosterone is added.
=== Elyzol dental gel - parodontitis === Camurus has partnered with Colgate-Palmolive for the marketing of their Elyzol dental gel for the treatment of parodontitis. Elyzol 25% dental gel contains metronidazole in the form of metronidazole benzoate as the active substance.
Unlike most modern eggs, many non-avian dinosaur eggs had a rough texture formed by nodes and ridges ornamenting the surface of their shell. This is predominant in Cretaceous dinosaur eggs, but very rare in eggs from the Jurassic or Triassic. Because of the lack of modern analogues, the purpose of eggshell ornamentation is unknown, but many functions have been proposed. Possibly, they provided extra strength to the eggshell without having pore canals too long for adequate gas exchange. They could also have helped keep substrate away from the pore openings of eggs that were buried, but modern turtles and crocodylians which bury their eggs have smooth eggshells, so this adaptation is not necessary for animals which bury their eggs. Another hypothesis, proposed by R. M. Mellon in 1982 in his senior thesis at Princeton University, is that the ridges and nodes would have formed pathways for gas to flow across the surface of the eggshell, preventing accumulation of too much CO2 and aiding the flow of oxygen and water vapor. Since it varies from egg to egg, the texture of an eggshell's ornamentation is useful for classification. Six types of ornamentation were catalogued by Carpenter in 1999:
Sources: en.wikipedia.org
=== Freeze-dried ingredients === Freeze-drying requires the use of heavy machinery and is not something that most campers can do on their own. Freeze-dried ingredients are often considered superior to dehydrated ingredients because they rehydrate at camp faster and retain more flavor than their dehydrated counterparts. Freeze-dried ingredients take so little time to rehydrate that they can often be eaten without cooking them first and have a texture similar to a crunchy chip. Small amounts of freeze-dried ingredients are sometimes available for sale from emergency supply outlets or stores specific to camping. Freeze-dried ingredients that have not been combined into a meal are often hard to find and thus tend to be sought out by campers. One of the first freeze-dried camping foods companies was Backpacker's Pantry in 1951, originally named Dri-lite Foods, invented after an ill-fated Girl Scout camping trip by Anne Benedict, becoming the first adventure food on the market.
==== Colours ==== Tulip flowers come in a wide variety of colours — reds, yellows, purples, white — except pure blue (several tulips with "blue" in the name have a faint violet hue), and do not have nectaries. The colour of a tulip is formed from two pigments working in concert; a base colour that is always yellow or white, and a second anthocyanin colour. The mix of these two hues determines the visible unitary colour. The breaking of flowers occurs when a virus suppresses anthocyanin production and the base colour is exposed as a streak. While tulips can be bred for many of colours, black tulips have historically been difficult to achieve. The Queen of the Night tulip is close to black, though it is a dark and glossy maroonish purple. The first truly black tulip was bred in 1986 by a Dutch flower grower in Bovenkarspel, Netherlands. It was created by cross-breeding two deep purple tulips, the Queen of the Night and Wienerwald tulips.
=== Diseases === Verticillium wilt is a major constraint in peppermint cultivation. 'Todd's Mitcham', 'Refined Murray', 'Roberts Mitcham' (see above), and a few other cultivars have some degree of resistance.
Sources: en.wikipedia.org
=== Policy and regulatory environment === In order for digital agriculture to spread, national governments, multilateral organizations, and other policymakers must provide a clear regulatory framework so that stakeholders feel confident investing in digital agriculture solutions. Policy designed for the pre-Internet era prevents the advancement of "smart agriculture," as does regulatory ambiguity. Furthermore, a blurry line between personal and business data when discussing family farms complicates data regulation. The unanswered regulatory questions mostly concern big data, and they include:
== Human proteins containing laminin domains == Laminin domain I: all laminin alpha chains (LAMA1, LAMA2, LAMA3, LAMA4, LAMA5) Laminin domain II: all laminin alpha chains (LAMA1, LAMA2, LAMA3, LAMA4, LAMA5) Laminin B (domain IV): all laminin alpha chains (LAMA1, LAMA2, LAMA3, LAMA4, LAMA5), gamma chains (LAMC1, LAMC2, LAMC3), and perlecan (HSPG2) Laminin EGF-like (domains III and V): all laminin chains (LAMA1, LAMA2, LAMA3, LAMA4, LAMA5, LAMB1, LAMB2, LAMB3, LAMB4, LAMC1, LAMC2, LAMC3), attractins (ATRN, ATRNL1), cadherin EGF LAG seven-pass G-type receptors (CELSR1, CELSR2, CELSR3), cysteine-rich with EGF-like domain proteins (CRELD1, CRELD2), multiple EGF-like domain proteins (MEGF6, MEGF8, MEGF9, MEGF10, PEAR1), most netrins (NTN1, NTN3, NTN4, NTNG1, NTNG2), mucins 3A and 3B (MUC3A, MUC3B), class F scavenger receptors (SCARF1, SCARF2), stabilins (STAB1, STAB2), agrin (AGRIN), angiopoietin-1 receptor (TEK), perlecan (HSPG2), tenascin N (TNN), and usherin (USH2A).
oxidation state Also oxidation number. 1. The degree of oxidation of an individual atom in a chemical compound, measured as the decrease in the number of electrons relative to the atom's naturally occurring elemental state. 2. The hypothetical electric charge (positive, negative, or zero) that an atom would have if all bonds to atoms of different elements were 100% ionic, with no covalent component.
The United States has an extensive air transportation network. U.S. civilian airlines are all privately owned. The three largest airlines in the world, by total number of passengers carried, are U.S.-based; American Airlines became the global leader after its 2013 merger with US Airways. Of the 50 busiest airports in the world, 16 are in the United States, as well as five of the top 10. The world's busiest airport by passenger volume is Hartsfield–Jackson Atlanta International in Atlanta, Georgia. In 2022, most of the 19,969 U.S. airports were owned and operated by local government authorities, and there are also some private airports. Some 5,193 are designated as "public use", including for general aviation. The Transportation Security Administration (TSA) has provided security at most major airports since 2001. The country's inland waterways are the world's fifth-longest, totaling 25,482 mi (41,009 km). They are used extensively for freight, recreation, and a small amount of passenger traffic. Of the world's 50 busiest container ports, four are located in the United States, with the busiest in the country being the Port of Los Angeles.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.